Related Articles
Clinical Rheumatology Year in Review—2022
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.
New ACR President Carol Langford, MD, MHS, Has Optimistic Outlook for Future of Rheumatology
“At my very first annual meeting of the ACR, I saw how the ACR brought the whole rheumatology community together, and I knew right away that it was an organization that I wanted to be a part of,” Dr. Langford says. In late November, she became the 88th president of the ACR and looks forward to continuing its focus on education, research and building community.
ACR Hosts Arthritis 101 Briefing on Capitol Hill
On Jan. 31, the ACR partnered with the Arthritis Foundation to host an Arthritis 101 Congressional briefing on Capitol Hill. Panelists educated new and returning members of Congress and their staffers about arthritis and other rheumatic diseases, the cost and impact of rheumatic disease to constituents and the U.S. healthcare system, and current policy challenges…
Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis
A recent study, conducted by the Vasculitis Clinical Research Consortium and funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), examined whether the addition of abatacept, a drug that affects T cell activation, to standard prednisone treatment could reduce the risk of relapse in patients with giant cell arteritis (GCA).1 Although…